diarrhea
patient
acquir
immun
defici
syndrom
aid
proven
diagnost
treatment
challeng
sinc
discoveri
human
immunodefici
viru
hiv
viru
year
ago
among
main
etiolog
diarrhea
group
patient
infecti
agent
span
array
virus
bacteria
protozoa
parasit
fungal
organ
mani
instanc
highli
activ
antiretrovir
therapi
remain
cornerston
therapi
aid
aidsrel
diarrhea
target
therapi
develop
new
pathogen
identifi
howev
infect
remain
treatment
challeng
identifi
infect
well
caus
diarrhea
investig
exclud
uniqu
entiti
known
aid
enteropathi
diagnos
known
idiopath
pathogenneg
diarrhea
diseas
investig
extens
atyp
viral
pathogen
includ
hiv
well
inflammatori
immunolog
respons
potenti
lead
caus
although
aid
enteropathi
pose
diagnost
challeng
treatment
highli
activ
antiretrovir
therapi
nutrit
supplement
electrolyt
replac
target
therapi
infect
indic
medic
symptom
control
key
element
treatment
regimen
importantli
multidisciplinari
approach
among
gastroenterologist
infecti
diseas
physician
hiv
specialist
oncolog
surgeri
necessari
mani
patient
abbrevi
use
paper
aid
acquir
immun
defici
syndrom
cmv
cytomegaloviru
galt
gutassoci
lymphoid
tissu
gi
gastrointestin
haart
highli
activ
antiretrovir
therapi
hiv
human
immunodefici
viru
mac
mycobacterium
avium
complex
oi
opportunist
infect
tb
tuberculosi
ore
million
peopl
worldwid
current
infect
human
immunodefici
viru
hiv
moreov
mani
perish
devast
diseas
begin
new
diseas
entiti
ultim
would
name
acquir
immun
defici
syndrom
aid
describ
among
patient
rural
uganda
zair
tanzania
unit
state
major
symptom
complex
involv
digest
tract
profound
weight
loss
malnutrit
sever
wateri
diarrhea
diseas
name
indigen
african
popul
slim
diseas
african
patient
poorli
understood
ill
liter
wast
away
serwadda
et
al
report
slim
diseas
appear
occur
predominantli
heterosexu
promiscu
popul
africa
time
believ
clear
indic
implic
mode
transmiss
insect
vector
inject
drug
use
uncertain
high
percentag
hivinfect
patient
worldwid
initi
present
ultim
develop
diarrhea
without
highli
activ
antiretrovir
therapi
haart
current
substanti
diarrhea
occur
hivinfect
individu
unit
state
develop
world
howev
diarrhea
may
occur
much
higher
preval
mani
hivinfect
individu
specif
enter
pathogen
isol
patient
undergo
exhaust
intens
standard
gastrointestin
gi
evalu
individu
sever
diarrhea
current
area
world
access
sophist
endoscop
evalu
specif
atyp
pathogen
like
found
nearli
patient
sever
stoolstudyneg
diarrhea
inde
colonoscopi
intub
biopsi
termin
ileum
togeth
endoscopi
upper
gi
tract
success
identifi
pathogen
patient
previous
term
idiopath
diarrhea
tabl
howev
everi
patient
hivassoci
diarrhea
need
complet
endoscop
evalu
full
endoscop
workup
necessari
patient
function
disabl
diarrhea
etiolog
unclear
mani
patient
diarrhea
lead
diminish
qualiti
life
smallbowel
mucos
diseas
routin
associ
profound
malnutrit
common
manifest
hiv
diseas
develop
world
diarrhea
earli
pervas
manifest
hiv
diseas
associ
increas
morbid
mortal
diarrhea
also
substanti
increas
health
care
cost
mani
patient
particularli
sever
secretori
diarrhea
malabsorptionmalnutrit
necessit
repeat
hospit
clinic
present
vari
among
patient
hivassoci
diarrhea
depend
princip
area
gi
tract
involv
smallbowel
diarrhea
tend
produc
larg
bulki
postprandi
stool
patient
smallbowel
diarrhea
fast
nutrient
signific
amount
diarrhea
convers
meal
patient
smallbowel
diarrhea
report
almost
immedi
postprandi
paraumbil
abdomin
pain
volumin
diarrhea
weight
loss
characterist
smallbowel
diarrhea
hand
larg
intestin
diarrhea
socal
colit
diarrhea
associ
frequent
smallvolum
stool
patient
commonli
becom
dehydr
colon
diarrhea
also
may
associ
presenc
visibl
blood
mucou
patient
largebowel
diarrhea
often
lowerquadr
abdomin
pain
andor
sensat
rectal
urgenc
mani
instanc
difficult
distinguish
largeand
smallbowel
diarrhea
base
clinic
present
alon
thu
highlight
need
exhaust
diagnost
evalu
past
decad
welldefin
subset
hivaid
patient
profound
diarrhea
malnutrit
wast
infecti
pathogen
identifi
caus
agent
emerg
kotler
et
al
note
alter
intestin
plasma
cell
aid
patient
without
identifi
point
time
intestin
pathogen
figur
hivinfect
patient
aidsrel
complex
fulli
express
aid
mean
villusheight
mean
villuscrypt
ratio
significantli
lower
normal
control
figur
use
immunofluoresc
stain
research
observ
decreas
immunoglobulin
ig
plasma
cell
rel
increas
igm
plasma
cell
small
bowel
colon
also
decreas
quantit
plasma
cell
fluoresc
sampl
stain
iga
igm
impli
less
cytoplasm
immunoglobulin
per
cell
howev
deplet
iga
plasma
cell
alway
correl
alter
serum
iga
concentr
kotler
et
al
also
note
lymphoid
deplet
patient
aid
might
patchi
might
involv
mani
cell
addit
plasma
cell
initi
specul
hiv
infect
cell
directli
within
epithelium
lamina
propria
temper
identif
atyp
virus
rare
search
gi
tract
patient
aidsrel
diarrhea
cunningham
et
al
first
identifi
rotavirus
adenovirus
enzymelink
immunosorb
assay
electron
microscopi
andor
cell
cultur
analys
virus
found
hivposit
symptomat
patient
diarrhea
less
hivneg
patient
less
hivposit
asymptomat
patient
without
diarrhea
appear
therefor
virus
occasion
associ
high
excret
rate
hivinfect
patient
diarrhea
might
associ
acut
episod
relaps
diarrhea
cunningham
et
al
also
postul
may
addit
yet
identifi
pathogen
patient
chronic
relaps
acut
diarrhea
grohmann
et
al
center
diseas
control
report
preval
wide
rang
enter
virus
hivinfect
patient
without
diarrhea
sixtyf
hivposit
patient
group
diarrhea
without
diarrhea
adenoviru
astroviru
picobiranviru
chronoviru
calicivirida
featureless
small
round
virus
note
stool
hivposit
patient
diarrhea
compar
hivinfect
patient
without
diarrhea
overal
fecal
specimen
patient
aid
refractori
diarrhea
harbor
virus
compar
stool
patient
without
diarrhea
tabl
thu
studi
report
socal
aid
enteropathi
alway
temper
realiti
virus
well
infecti
agent
ultim
may
found
patient
socal
idiopath
aidsrel
diarrhea
one
need
recal
belatedli
identifi
pathogen
mycobacteriumavium
complex
cryptosporidium
microsporidium
patient
previous
term
idiopath
aid
diarrhea
recogn
real
potenti
unsuspect
unidentifi
pathogen
bowel
mani
investig
found
hiv
infect
enterocyt
lamina
propria
cell
submucosa
nelson
et
al
figur
comparison
mean
villuscrypt
ratio
b
mean
villusheight
ratio
c
mean
crypt
depth
among
aid
patient
without
diarrhea
normal
control
arc
aidsrel
complex
reprint
permiss
greenson
jk
et
al
use
situ
hybrid
biopsi
specimen
obtain
rectum
duodenum
show
hivinfect
cell
base
crypt
within
lamina
propria
postul
associ
situ
label
hiv
rna
argentaffin
cell
strongli
suggest
enterochromaffin
cell
deriv
neural
crest
tissu
may
fact
among
primari
target
cell
hiv
along
line
batman
et
al
describ
jejun
enteropathi
associ
hiv
degre
villu
atrophi
jejun
mucosa
estim
use
widal
eye
piec
graticul
jejun
villu
enterocyt
show
mild
nonspecif
abnorm
crypt
hyperplasia
recur
stage
hiv
diseas
even
absenc
pathogen
suggest
pathogenesi
villu
atrophi
actual
immun
reaction
within
lamina
propria
cell
infect
hiv
delezay
et
al
report
find
vitro
studi
differenti
epitheli
cell
clone
note
hiv
impair
cellular
differenti
barrier
function
sodiumglucos
cotransport
epitheli
cell
line
hiv
massiv
disrupt
microtubul
reveal
indirect
immunofluoresc
stain
investig
suggest
hiv
perturb
intestin
function
without
infect
epitheli
cell
opportunist
disord
exclud
patient
refractori
diarrhea
hiv
enteropathi
exist
small
definit
percentag
popul
batman
et
al
studi
crypt
stem
transit
cell
prolifer
studi
kinet
stem
transit
cell
line
note
definit
villu
atrophi
induc
microsporidia
hiv
infect
provok
crypt
cell
hypertrophi
includ
encroach
crypt
cell
onto
villi
stimul
cell
mitos
stem
transit
cell
dandekar
clarifi
pathogenesi
hiv
diseas
gi
tract
note
gutassoci
lymphoid
tissu
galt
clearli
earli
site
hiv
replic
tcell
deplet
addit
studi
support
hiv
destroy
galt
earli
stage
hiv
infect
initi
haart
lead
complet
suppress
viral
replic
partial
restor
tcell
galt
compar
peripher
blood
appear
persist
hiv
replic
galt
lead
crypt
alter
mainten
hiv
reservoir
knox
et
al
describ
function
disrupt
gi
tract
caus
hiv
among
patient
hiv
infect
diarrhea
stool
pathogen
identifi
patient
despit
patient
abnorm
dxylos
test
borderlin
low
serum
level
depress
albumin
level
investig
suggest
abnorm
gi
tract
common
even
era
modern
haart
clinician
therefor
care
must
exclud
identifi
pathogen
even
patient
haart
monkemul
et
al
note
sinc
patient
provid
specimen
enrol
earli
studi
differ
time
either
new
onset
diarrhea
case
patient
period
without
diarrhea
control
p
valu
calcul
fisher
exact
test
b
three
patient
acut
episod
astrovirusassoci
diarrhea
one
occas
c
srsv
norwalklik
virus
consid
member
famili
calicivirida
along
human
calicivirus
taken
togeth
calicivirida
associ
margin
diarrhea
p
specimen
p
patient
patient
without
diarrhea
shed
picobirnaviru
differ
time
picobirnavirusassoci
diarrhea
categori
patient
includ
case
patient
control
e
total
number
specimen
viru
present
singl
mix
infect
patient
infect
one
type
viru
f
mix
infect
consist
case
adenoviru
astroviru
case
caliciviru
coronaviruslik
particl
case
adenoviru
coronaviruslik
particl
widespread
use
haart
dramat
decreas
preval
identifi
opportunist
infect
gi
tract
opportunist
infect
still
occur
examin
popul
patient
treat
haart
patient
men
mean
age
year
studi
patient
mean
tcell
count
mean
rna
viral
load
copi
per
ml
despit
treat
haart
patient
identifi
opportunist
disord
gi
tract
care
question
howev
identifi
approxim
patient
new
persist
opportunist
disord
gi
tract
like
definit
noncompli
administ
haart
thu
gi
opportunist
disord
still
occur
hivposit
patient
includ
allegedli
take
haart
especi
low
tcell
count
high
hiv
viral
load
unfortun
opportunist
disord
still
occur
patient
nearnorm
tcell
count
low
hiv
viral
load
thu
hiv
enteropathi
associ
increas
inflamm
immun
activ
decreas
mucos
repair
regenerationthes
contribut
presenc
hiv
enteropathi
sankaran
et
al
highlight
import
galt
earli
target
hiv
infect
site
sever
tcell
deplet
note
viral
replic
occur
earli
primari
hiv
infect
galt
cell
macrophag
also
decreas
express
level
gene
regul
epitheli
barrier
mainten
digest
metabol
function
chang
coincid
decreas
transcript
immun
activ
inflamm
apoptosisassoci
gene
consequ
hiv
infect
galt
occur
molecular
cellular
level
even
seroconvers
although
hiv
enteropathi
encompass
idiopath
pathogenneg
diarrhea
array
opportunist
infect
oi
invad
gi
tract
patient
advanc
hiv
gi
oi
includ
complex
milieu
bacteria
fungu
virus
protozoa
typic
exert
devast
effect
patient
tcell
count
decreas
less
cellsl
figur
studi
gi
oi
undergon
astonish
transform
past
year
mark
period
remark
discoveri
innov
term
identifi
new
pathogen
suitabl
treatment
similar
evolv
treatment
infect
role
gastroenterologist
circumst
chang
time
well
mani
case
multidisciplinari
approach
among
gastroenterolog
infecti
diseas
hiv
specialist
oncolog
surgeri
encourag
mani
case
requir
treat
hiv
patient
gi
oi
advent
haart
revolution
treatment
hiv
result
strike
declin
hivrel
infect
associ
mortal
addit
haart
mark
sustain
continu
declin
incid
preval
gi
oi
dramat
declin
illustr
superbl
monkemul
et
al
prospect
studi
univers
alabama
birmingham
examin
aid
patient
undergo
dual
endoscopi
gi
complaint
time
period
interv
discov
incid
gi
oi
decreas
peak
nadir
wherea
time
haart
use
patient
increas
sever
multifactor
theori
propos
explain
declin
gi
oi
one
reestablish
patient
natur
immun
repopul
cell
enter
mucosa
combat
variou
opportunist
pathogen
previous
could
fight
second
explan
may
direct
effect
haart
regimen
specif
pathogen
within
combin
haart
proteas
inhibitor
observ
vivo
vitro
inhibitori
properti
specif
organ
via
degrad
aspartyl
proteas
regardless
mechan
haart
extraordinari
success
treat
hivassoci
gi
oi
sinc
introduct
success
haart
span
across
entir
assort
gi
oi
exampl
multipl
studi
uniformli
shown
decreas
incid
cryptospo
ridium
microsporidium
respons
haart
likewis
influenti
studi
carr
et
al
discov
hiv
patient
infect
cryptosporidium
parvum
enterocytozoon
bieneusi
fail
previou
antimicrobi
therapi
full
clinic
histolog
microbiolog
respons
haart
addit
major
patient
remain
symptom
free
year
recurr
symptom
declin
tcell
count
howev
interplay
haart
treatment
gi
oi
limit
parasit
fungal
organ
stori
unravel
eloqu
sever
studi
treatment
patient
cytomegaloviru
cmv
infect
hiv
patient
combin
haart
consist
greater
rate
surviv
compar
haartnaiv
patient
even
adjust
cmv
therapi
accordingli
profound
effect
haart
treat
gi
oi
unquestion
frontlin
therapi
mani
gi
oi
although
effect
haart
compel
research
note
occurr
gi
oi
despit
use
haart
subset
patient
factor
medic
noncompli
resist
strain
hiv
late
initi
haart
poor
bioavail
haart
could
role
inabl
alway
treat
oi
situat
underscor
need
continu
target
therapi
oi
circumst
despit
use
haart
tabl
although
rate
gi
parasit
infect
declin
time
pathogen
cryptosporidia
isospora
cyclospora
continu
contribut
morbid
mortal
among
aid
patient
diarrhea
cryptosporidiosi
challeng
treat
year
intracellular
locat
within
enterocyt
innat
resist
respons
dilemma
although
haart
reduc
incid
cryptosporidiosi
among
hiv
patient
lead
complet
resolut
diarrhea
pathogen
erad
mani
occas
unfortun
mani
part
world
patient
access
haart
limit
year
main
therapi
emerg
potenti
treatment
cryptosporidiosi
nitazoxanid
paromomycin
howev
clinic
studi
agent
limit
small
sampl
size
lack
enrol
patient
hiv
small
number
random
control
trial
conflict
result
cochran
metaanalysi
attempt
address
resolv
issu
metaanalysi
studi
nitazoxanid
therapi
compar
placebo
indic
nitazoxanid
effect
cure
parasit
infect
patient
overal
data
patient
hiv
statist
signific
hiv
patient
tend
less
resolut
diarrheal
ill
interestingli
random
studi
includ
metaanalysi
examin
nitazoxanid
therapi
hiv
patient
sever
strike
differ
initi
studi
rossignol
et
al
show
hiv
patient
cryptosporidi
diarrhea
tcell
count
cellsl
greater
cure
rate
compar
placebo
week
nitazoxanid
therapi
convers
year
later
amadi
et
al
examin
children
aid
found
short
cours
nitazoxanid
therapi
result
reduc
stool
volum
increas
fecal
oocyt
clearanc
improv
mortal
hivneg
children
show
similar
result
hivposit
children
one
could
argu
treatment
durat
week
compar
day
well
patient
popul
adult
vs
pediatr
make
compar
draw
cohes
conclus
studi
challeng
fuel
debat
multicent
prospect
evalu
aid
patient
cryptosporidiosi
treat
nitazoxanid
largest
studi
date
nitazoxanid
therapi
hivrel
cryptosporidiosi
studi
subject
adult
studi
show
patient
achiev
clinic
respons
cultureneg
stool
cultur
nitazoxanid
therapi
patient
higher
tcell
count
like
achiev
continu
clinic
respons
larger
random
placebocontrol
trial
nitazoxanid
therapi
hiv
patient
warrant
definit
recommend
treatment
made
although
current
evid
appear
support
use
nitazoxanid
hiv
adult
patient
prolong
cours
better
respons
rate
observ
patient
robust
cellular
immun
along
line
paromomycin
equivoc
result
time
studi
paromomycin
includ
far
fewer
hiv
patient
compar
studi
nitazoxanid
cochran
metaanalysi
show
slight
trend
toward
effect
treatment
use
paromomycin
overal
rel
risk
decreas
stool
frequenc
oocyt
clearanc
modest
statist
signific
compar
random
trial
nitazoxanid
paromomycin
therapi
appreci
disappoint
contradictori
result
hewitt
et
al
show
paromomycin
therapi
result
partial
complet
clinic
respons
placebo
conclud
paromomycin
ineffect
treat
symptomat
cryptosporidi
diarrheal
diseas
earlier
studi
white
et
al
report
paromomycin
might
result
clinic
improv
patient
aid
cryptosporidi
diarrhea
improv
short
live
associ
high
relaps
rate
approach
therapi
discontinu
unfortun
trial
compar
paromomycin
nitazoxanid
therapi
directli
thu
paromomycin
might
efficaci
treat
symptomat
cryptosporidi
diarrhea
appear
less
consist
nitazoxanid
alway
lead
sustain
respons
plethora
agent
studi
treatment
hiv
cryptosporidi
diarrhea
spiramycin
bovin
dialyz
leukocyt
extract
bovin
hyperimmun
colostrum
investig
rigor
random
control
clinic
trial
also
includ
cochran
metaanalysi
drug
compar
placebo
ineffect
either
reduc
stool
volum
cure
patient
parasit
infect
clarithromycin
octreotid
atovaquon
tri
limit
success
horizon
combin
paromomycin
plu
azithromycin
well
use
rifaximin
alon
shown
encourag
result
improv
symptom
decreas
cryptosporidi
oocyt
excret
especi
hiv
patient
refractori
therapi
thu
current
evid
strongli
support
use
haart
proteas
inhibitor
part
regimen
initi
therapi
patient
cryptosporidiosi
haart
clearli
shown
persist
clinic
effect
abil
cure
parasit
infect
mani
hivinfect
patient
patient
continu
sever
diarrheal
diseas
despit
haart
improv
tcell
function
addit
nitazoxanid
therapi
consid
howev
nitazoxanid
therapi
alon
inappropri
without
haart
treatment
option
isosporiasi
definit
mainstay
therapi
trimethoprimsulfamethoxazol
mg
oral
time
day
day
given
high
relaps
rate
nearli
regimen
usual
follow
secondari
prophylaxisespeci
patient
haart
start
tcell
count
continu
remain
less
cellsl
although
ciprofloxacin
less
effect
compar
directli
trimethoprimsulfamethoxazol
success
rate
greater
resolv
symptom
cure
hiv
patient
isosporiasi
infect
altern
regimen
patient
toler
fail
trimethoprimsulfamethoxazol
andor
ciprofloxacin
includ
nitazoxanid
pyrimethamin
similarli
cyclosporiasi
treat
trimethoprim
sulfamethoxazol
mg
oral
time
day
day
similar
efficaci
isosporiasi
secondari
prophylaxi
trimethoprimsulfamethoxazol
may
necessari
patient
haart
low
tcell
count
lesseffect
regimen
includ
ciprofloxacin
nitazoxanid
microsporidium
reclassifi
fungu
long
associ
infect
small
bowel
patient
advanc
hiv
encephalitozoan
intestinali
enterocytozoon
bieneusi
preval
speci
encount
immunocompromis
patient
similar
treatment
cryptosporidiosi
restor
patient
innat
immun
system
haart
paramount
import
treat
hiv
patient
microsporidium
infect
haart
alon
result
cessat
diarrhea
consider
weight
gain
wast
patient
complet
erad
organ
determin
microbiolog
histolog
analys
mani
patient
addit
immun
reconstitut
sever
therapi
evolv
time
treat
microsporidium
treatment
encephalitozoan
intestinali
remain
unchang
past
sever
year
includ
albendazol
benzimidazol
inhibit
tubulin
polymer
albendazol
therapi
encephalitozoan
intestinali
consist
result
complet
organ
erad
hivposit
patient
contrast
enterocytozoon
bieneusi
proven
challeng
difficult
entiti
treat
success
achiev
albendazol
although
pathogen
suppress
incomplet
inconsist
fumagillin
antibiot
antiangiogen
properti
show
encourag
result
earli
studi
improv
hiv
symptom
fecal
clearanc
organ
unfortun
high
rate
bone
marrow
toxic
limit
use
drug
within
unit
state
never
receiv
food
drug
administr
approv
consequ
analogu
develop
show
success
vivo
vitro
studi
made
way
human
clinic
trial
treatment
enterocytozoon
bieneusi
host
agent
either
limit
success
disappoint
result
studi
potenti
agent
limit
fact
efficaci
shown
case
report
small
seri
patient
vitro
vivo
studi
therapi
includ
nitazoxanid
atovaquon
itraconazol
metronidazol
octreotid
thalidomid
trimethoprimsulfamethoxazol
overal
diagnosi
microsporidium
confirm
treatment
begin
promptli
combin
haart
well
electrolyt
replac
symptom
manag
encephalitozoan
intestinali
treat
success
albendazol
although
moment
avail
effect
therapi
unit
state
enterocytozoon
bieneusi
array
fungal
organ
infect
gi
tract
caus
sever
morbid
mortal
organ
usual
rare
geograph
distinct
mostli
occur
diseas
dissemin
fungal
oi
may
encount
unit
state
includ
histoplasmosi
cryptococcosi
mani
case
gi
sign
symptom
obscur
widespread
infect
usual
pulmonari
central
nervou
system
unusu
infect
local
specif
gi
tract
although
report
given
strong
interact
system
diseas
gi
involv
mainstay
therapi
infect
focus
treatment
dissemin
diseas
gi
system
infect
similar
treat
origin
induct
phase
control
clinic
sign
follow
prolong
mainten
phase
relaps
prevent
commonli
amphotericin
b
either
deoxychol
liposom
formul
use
induct
phase
follow
mainten
therapi
either
fluconazol
itraconazol
longterm
mainten
therapi
could
requir
patient
haart
persist
low
tcell
count
lastli
import
treat
gi
oi
restor
patient
immun
system
haart
sever
virus
implic
hiv
esophagitisenteritiscol
year
notabl
cmv
vast
major
patient
viral
pathogen
infect
gi
tract
treat
haart
well
support
care
electrolyt
imbal
symptom
control
howev
cmv
gi
diseas
proven
uniqu
challeng
compar
virus
nearli
cmv
infect
occur
gi
tract
preval
cmv
coliti
hiv
patient
diarrhea
rang
although
data
avail
treatment
cmv
gi
diseas
vast
major
studi
focus
cmv
retin
treatment
recommend
cmv
gi
diseas
come
studi
import
treat
cmv
promptli
given
poor
prognosi
high
rate
recurr
treatment
cmv
infect
gi
tract
commenc
either
ganciclovir
foscarnet
week
time
frame
therapi
vari
patient
monitor
sign
clinic
improv
determin
length
treatment
time
requir
clinic
trial
support
use
either
ganciclovir
foscarnet
initi
treatment
open
random
studi
patient
cmv
gi
diseas
treat
either
foscarnet
ganciclovir
show
either
drug
led
similar
improv
clinic
symptom
resolut
endoscop
find
disappear
inclus
bodi
biopsi
although
subsequ
mainten
regimen
requir
therapi
cmv
retin
debat
continu
mainten
therapi
patient
gi
cmv
relaps
rate
week
year
cmv
gi
tract
diseas
report
fuel
controversi
limit
studi
shown
benefit
mainten
therapi
mainten
therapi
consid
patient
continu
symptom
despit
complet
cours
therapi
patient
recur
diseas
need
mainten
therapi
may
negat
introduct
haart
patient
medic
regimen
aid
patient
cmv
retin
haart
shown
fewer
relaps
continu
cmv
viral
suppress
case
abl
discontinu
mainten
therapi
complet
factor
coupl
improv
surviv
point
haart
integr
posit
treatment
cmv
infect
gi
tract
appropri
time
initi
haart
patient
gi
cmv
diseas
sourc
controversi
unfortun
limit
data
avail
subject
given
theoret
risk
develop
immun
reconstitut
syndrom
mani
clinician
advoc
delay
haart
acut
symptom
diseas
resolv
cmv
therapi
convers
clinician
argu
start
haart
alon
patient
mild
moder
cmv
gi
diseas
safe
reason
first
step
rather
initi
start
direct
cmv
therapi
data
therapeut
strategi
lack
time
haart
andor
cmv
therapi
made
care
consider
patient
clinic
statu
well
commun
patient
primari
hiv
physician
potenti
haart
initi
past
sever
year
oral
valganciclovir
appear
attract
regimen
place
intraven
form
ganciclovir
foscarnet
current
random
control
trial
compar
valganciclovir
either
ganciclovir
foscarnet
treatment
cmv
gi
diseas
perform
encourag
evid
treatment
cmv
retin
cmv
diseas
solid
organ
transplant
prompt
physician
consid
use
initi
therapi
given
indirect
evid
societi
recommend
use
oral
valganciclovir
therapi
unless
symptom
prevent
patient
take
oral
medic
andor
symptom
sever
enough
result
intestin
malabsorpt
thu
decreas
drug
bioavail
lastli
limit
data
approach
patient
treatment
failur
gi
cmv
major
studi
topic
deal
cmv
retin
potenti
option
includ
begin
chronic
mainten
therapi
initi
drug
use
valganciclovir
optim
haart
ensur
adequ
restor
cellular
immun
chang
altern
drug
use
initi
regimen
last
resort
use
combin
therapi
ganciclovir
foscarnet
numer
bacteri
infect
occur
frequent
virul
pattern
hiv
patient
includ
salmonella
shigella
campylobact
jejuni
age
hiv
prophylaxi
widespread
use
antibiot
clostridium
difficil
fact
c
difficileassoci
diarrhea
rank
common
bacteri
infect
observ
hiv
patient
diarrhea
howev
realm
gi
oi
mycobacteri
diseas
specif
mycobacterium
avium
complex
mac
mycobacterium
tuberculosi
tb
predomin
role
hivinfect
patient
gi
mac
usual
dissemin
diseas
low
tcell
count
limit
surviv
time
introduct
haart
well
prophylaxi
incid
preval
dissemin
mac
decreas
year
mac
treatment
evolv
multidrug
cours
antibiot
prolong
time
indefinit
period
therapi
initi
firstlin
treatment
mac
consist
antibiot
clarithromycin
ethambutol
agent
alon
high
rate
drug
resist
wherea
combin
result
complet
microbiolog
respons
lower
relaps
rate
improv
clinic
symptom
overal
better
surviv
addit
third
agent
rifabutin
shown
increas
surviv
time
ad
benefit
less
resist
also
ad
earlierdescrib
treatment
armamentarium
lastli
nation
institut
healthcent
diseas
controlhiv
medicin
associ
infecti
diseas
societi
america
guidelin
recommend
addit
either
inject
amikacin
streptomycin
therapi
patient
high
risk
death
mac
includ
patient
tcell
count
cellsl
less
high
mycobacteri
load
absenc
haart
unfortun
mac
treatment
lifelong
immun
function
improv
haart
mani
clinician
societi
advoc
delay
initi
haart
patient
haartnaiv
week
mac
therapi
begun
goal
delay
haart
therapi
severalfold
includ
reduc
drug
interact
increas
medic
complianc
avoid
complic
immun
reconstitut
syndrom
thorough
review
immun
reconstitut
syndrom
role
mac
therapi
well
opportunist
infect
pleas
see
nation
institut
healthcent
diseas
controlhiv
medicin
associationinfecti
diseas
societi
america
tb
treatment
guidelin
oi
infect
lastli
newer
adjuv
regimen
consist
inject
pulmonari
mac
patient
promis
result
addit
result
higher
respons
rate
earlier
improv
symptom
significantli
less
diseaserel
death
compar
current
standard
care
unfortun
clinic
trial
test
effect
patient
dissemin
mac
tb
gi
tract
affect
immunocompromis
immunocompet
patient
gi
tb
account
tb
case
worldwid
repres
less
tb
case
unit
state
commonli
found
region
ileocec
valv
tb
gi
tract
found
almost
anywher
coexist
time
pulmonari
tb
mimic
varieti
infecti
inflammatori
condit
gi
tract
treatment
intestin
tb
similar
pulmonari
extrapulmonari
form
tb
term
regimen
use
test
drug
suscept
ensur
complet
patient
adher
treatment
regimen
although
studi
abdomin
tb
treatment
confirm
multidrug
regimen
minimum
month
effect
therapi
term
microbiolog
clinic
respons
current
recommend
regimen
hivposit
patient
consist
ethambutol
rifampin
rifabutin
isoniazid
pyrazanimid
initi
phase
follow
continu
phase
isoniazid
rifampin
rifabutin
durat
therapi
vari
hiv
patient
depend
function
immun
system
drug
suscept
improv
clinic
symptom
although
surgeri
common
past
today
reserv
patient
complic
respond
medic
therapi
includ
obstruct
strictur
abscess
perfor
altern
regimen
medic
studi
propos
patient
medic
intoler
drug
suscept
haarttb
drug
interact
initi
haart
treatment
failur
regimen
recurr
diseas
see
nation
institut
healthcent
diseas
controlhiv
medicin
associationinfecti
diseas
societi
america
tb
treatment
guidelin
comprehens
discuss
offer
patient
aidsassoci
diarrhea
specif
target
therapi
exhaust
wilcox
saag
shown
haart
suppress
patient
viral
load
undetect
rang
stop
destruct
lymphocyt
cours
diarrheal
diseas
revers
dramat
patient
compliant
treatment
howev
mani
patient
haart
revers
cours
diarrhea
systemat
reason
algorithm
undertaken
figur
mani
patient
aidsrel
diarrhea
sever
malnourish
andor
recurr
dehydr
element
diet
sometim
help
particularli
contain
mediumchain
triglycerid
use
shortterm
hy
peraliment
whether
alimentari
intraven
rout
may
need
earli
treatment
program
regardless
initi
haart
occasion
multivitamin
miner
defici
detect
likewis
need
correct
proper
supplement
care
analysi
stool
sampl
essenti
obligatori
first
diagnost
step
enter
pathogen
isol
patient
treat
appropri
possibl
avail
agent
outlin
earlier
tabl
exhaust
stool
studi
pathogen
isol
factor
believ
contribut
diarrheal
diseas
clearli
role
addit
invas
endoscop
evalu
particularli
patient
sever
refractori
dehydr
diarrhea
decis
perform
complet
gi
evalu
consist
upper
endoscopi
smallbowel
biopsi
colonoscopi
biopsi
must
made
conjunct
patient
primari
care
provid
given
innumer
endoscop
modal
avail
gastroenterolog
sophist
patholog
laboratori
littl
reason
avoid
refus
invas
diagnost
test
patient
could
benefit
target
therapi
surprisingli
rare
patient
profound
wateri
diarrhea
malnutrit
found
ingest
agent
either
inadvert
surreptiti
associ
diarrhea
cathart
includ
lactos
sorbitol
mannitol
even
overthecount
cathart
diet
agent
clearli
consid
proscrib
intak
must
elimin
also
worthwhil
extens
review
patient
haart
regimen
mani
haart
medic
particular
proteas
inhibitor
nelfinavir
fosamprenavir
ritonavir
well
known
caus
diarrhea
antimotil
agent
loperamid
diphenoxyl
codein
adsorb
bismuth
subsalicyl
kaolinpectin
wide
avail
gener
attempt
somewhat
help
treat
mild
moder
diarrhea
gi
antimotil
agent
univers
opioid
decreas
stool
output
decreas
gi
motil
increas
transit
time
thu
gener
promot
fluid
electrolyt
absorpt
antimotil
adsorb
drug
reason
help
patient
mild
moder
pathogenneg
diarrhea
insuffici
evid
support
routin
use
probiot
andor
herbal
remedi
aid
patient
sever
diarrhea
patient
tri
sever
agent
describ
earlier
seek
medic
attent
addit
nonstandard
therapi
run
gamut
nonsteroid
antiinflammatori
drug
clonidin
tinctur
opium
octreotid
mani
clinic
studi
evalu
octreotid
patient
aidsrel
diarrhea
studi
rang
size
patient
overal
clinic
respons
rate
subcutan
octreotid
rang
studi
studi
patient
extens
investig
refractori
diarrhea
one
third
patient
ultim
found
cryptosporidium
infect
highlight
import
organ
develop
refractori
diarrhea
nearli
one
third
patient
studi
true
idiopath
diarrhea
pathogen
identifi
stool
studi
endoscop
examin
doubleblind
placebocontrol
trial
patient
assign
randomli
group
given
octreotid
mcg
mcg
mcg
placebo
time
day
end
trial
arithmet
statist
signific
differ
group
patient
idiopath
diarrhea
appear
fare
better
identifi
pathogen
although
differ
statist
signific
patient
given
octreotid
achiev
control
diarrheal
symptom
compar
placebo
group
signific
differ
group
respect
stool
frequenc
doubleblind
phase
trial
extend
week
openlabel
phase
figur
signific
reduct
stool
weight
week
respect
stool
frequenc
differ
observ
group
given
octreotid
given
placebo
control
trial
trial
extend
openlabel
phase
patient
data
compar
baselin
statist
signific
decreas
stool
frequenc
conclus
refractori
diarrhea
complex
problem
among
patient
hiv
diseas
investig
occur
earli
diseas
cours
includ
care
medic
histori
physic
examin
well
stool
studi
basic
laboratori
analys
infect
nutrit
statu
electrolyt
derang
potenti
moreinvas
endoscop
radiograph
evalu
etiolog
aid
refrac
tori
diarrhea
vast
encompass
spectrum
chronic
diarrheal
diseas
inflict
nonhivinfect
patient
well
etiolog
infect
medic
specif
hiv
immunocompromis
patient
interest
entiti
known
aid
enteropathi
emerg
evolv
year
reflect
idiopath
pathogenneg
diarrhea
whose
underli
caus
might
involv
undiscov
infecti
pathogen
inflammatori
chang
within
gi
tract
caus
hiv
environmentalinfecti
agent
hiv
complex
interplay
among
one
etiolog
aid
refractori
diarrhea
pose
diagnost
treatment
challeng
haart
nutrit
supplement
electrolyt
replac
target
therapi
specif
infect
allevi
symptom
key
element
treatment
regimen
patient
overal
care
challeng
patient
diagnosi
treatment
also
involv
effect
commun
teamwork
among
varieti
medic
surgic
specialti
